Synovial Sarcoma Research Pipeline Grows as 15+ Companies Develop New Therapies
Recent industry analyses show that the synovial sarcoma clinical trial pipeline is expanding, with more than 15 companies developing over…
Targeted Therapy Shows Promise in Rare BRAF-Mutated Synovial Sarcoma
Synovial sarcoma is a rare soft tissue sarcoma most commonly treated with surgery, chemotherapy, radiation therapy, and targeted drugs such…
Synovial Sarcoma Treatment Market Growth Reflects Expanding Research
Recent industry analyses suggest the synovial sarcoma treatment market is expected to grow steadily, with projections estimating a compound annual…
A Turning Point for Rare Cancers
What the UK’s Rare Cancers Bill Means for the Synovial Sarcoma Community For decades, patients diagnosed with rare cancers have…
Afamitresgene Autoleucel (Afami-cel): T-Cell Therapy Shows Promise in Synovial Sarcoma
Synovial sarcoma is a rare and often aggressive cancer that can become difficult to treat once it spreads. Traditional chemotherapy…
Synovial Sarcoma Foundation Hosts Second Community Webinar Highlighting Research Momentum
On February 19, 2026, the Synovial Sarcoma Foundation brought together patients, families, clinicians, and researchers from around the world for…
Rethinking the Driver: New Research Identifies P300 as a Critical Co-Factor in Synovial Sarcoma
Synovial sarcoma is driven by a defining genetic event — the SS18-SSX fusion protein, present in nearly all cases. For…
Synovial Sarcoma Treatment Market Projected to Grow Through 2031: What This Means for Patients
A recent market analysis estimates that the global synovial sarcoma treatment market was valued at approximately $832 million in 2023…
Join the Upcoming Synovial Sarcoma Webinar
Join the Synovial Sarcoma Foundation for a live, one-hour webinar focused on where synovial sarcoma research is heading and what…